wsbdaily | Tue, 20 Dec 2022 03:11:27 EST Where you find Tomorrow’s Hot Stocks Yesterday!
NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
Rigel Pharmaceuticals, Inc.(RIGL)
Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco, CA 94080
United States
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 pa... Read More
Summary & Charts
| Price | $ 1.26 | -0.22 (-14.87%) |
| Day's Range | $ 1.16 - 1.48 | |
| Previous Close | $ 1.48 | |
| Market Cap | $ 219.5M USD | |
| Short Interest % | 2.37 % | As of Fri, 14 Jan 2022 |
| Float | 170.8M | |
| Outstanding | 172.84M |
| Exchange | NasdaqGS | |
| Industry | Biotechnology | |
| Sector | Healthcare | |
| Volume | 6.53M | |
| Avg. Volume (20 day) | 7.54M | |
| Rel. Volume (20 day) | 0.87 | |
| Rel. Volume (3 month) | 1.79 | |
| Rating | B- | Neutral |
| DCF | N/A | Strong Buy |
| Debt/Equity | -682.88 % | Strong Sell |
| ROE | -2419.00 % | Strong Buy |
| ROA | -71.46 % | Sell |
| P/E | -2.54 % | Sell |
| P/B | -10.98 % | Strong Sell |
| Date | Open | High | Low | Close | Change | Volume | R. Vol. (20d) | R. Vol. (3m) | Mentions |
|---|---|---|---|---|---|---|---|---|---|
| Dec 19, 2022 | $ 1.46 | $ 1.48 | $ 1.16 | $ 1.26 | -0.22 | 6,526,776 | 0.87 | 1.79 | 1 |
| Dec 16, 2022 | $ 1.30 | $ 1.55 | $ 1.27 | $ 1.48 | +0.21 | 11,696,545 | 1.61 | 2.89 | 1 |
| Dec 15, 2022 | $ 1.06 | $ 1.36 | $ 1.05 | $ 1.27 | +0.17 | 6,498,816 | 0.96 | 1.64 | |
| Dec 14, 2022 | $ 1.05 | $ 1.15 | $ 1.01 | $ 1.10 | +0.02 | 3,312,564 | 0.51 | 0.83 | |
| Dec 13, 2022 | $ 1.03 | $ 1.10 | $ 0.98 | $ 1.08 | +0.09 | 4,545,509 | 0.71 | 1.15 | |
| Dec 12, 2022 | $ 0.90 | $ 1.05 | $ 0.86 | $ 0.99 | +0.12 | 4,500,390 | 0.72 | 1.15 | |
| Dec 09, 2022 | $ 0.90 | $ 0.91 | $ 0.85 | $ 0.87 | -0.03 | 1,888,303 | 0.31 | 0.49 | |
| Dec 08, 2022 | $ 0.85 | $ 0.93 | $ 0.84 | $ 0.90 | +0.01 | 2,333,082 | 0.39 | 0.60 | |
| Dec 07, 2022 | $ 0.93 | $ 0.94 | $ 0.86 | $ 0.89 | -0.03 | 4,210,421 | 0.70 | 1.08 | |
| Dec 06, 2022 | $ 0.97 | $ 1.03 | $ 0.90 | $ 0.92 | -0.03 | 12,520,707 | 2.15 | 3.25 | |
| Dec 05, 2022 | $ 0.84 | $ 0.96 | $ 0.82 | $ 0.95 | +0.12 | 18,835,501 | 3.58 | 5.04 | |
| Dec 02, 2022 | $ 0.94 | $ 0.99 | $ 0.82 | $ 0.83 | +0.15 | 60,097,147 | 13.77 | 17.04 | 1 |
| Dec 01, 2022 | $ 0.68 | $ 0.71 | $ 0.67 | $ 0.68 | +0.01 | 2,827,866 | 1.94 | 1.03 | |
| Nov 30, 2022 | $ 0.70 | $ 0.73 | $ 0.67 | $ 0.67 | -0.03 | 3,796,248 | 2.64 | 1.39 | |
| Nov 29, 2022 | $ 0.71 | $ 0.74 | $ 0.69 | $ 0.70 | -0.01 | 988,762 | 0.71 | 0.36 | |
| Nov 28, 2022 | $ 0.75 | $ 0.75 | $ 0.70 | $ 0.71 | -0.04 | 1,174,332 | 0.82 | 0.43 | |
| Nov 25, 2022 | $ 0.76 | $ 0.77 | $ 0.72 | $ 0.75 | -0.01 | 691,061 | 0.48 | 0.25 | |
| Nov 23, 2022 | $ 0.77 | $ 0.81 | $ 0.75 | $ 0.76 | -0.02 | 730,543 | 0.50 | 0.26 | |
| Nov 22, 2022 | $ 0.76 | $ 0.80 | $ 0.73 | $ 0.78 | -0.00 | 2,087,289 | 1.38 | 0.74 | |
| Nov 21, 2022 | $ 0.76 | $ 0.79 | $ 0.74 | $ 0.78 | +0.02 | 1,551,629 | 1.07 | 0.54 |
News
The latest news about Rigel Pharmaceuticals, Inc. (RIGL).
Zacks Investment Research | 2022-12-02 14:18:19
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
InvestorPlace | 2022-12-02 11:17:52
Rigel Pharmaceuticals (NASDAQ: RIGL ) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for its leukemia treatment. Specifically, the FDA has approved REZLIDHIA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation.
Market Watch | 2022-12-02 06:37:20
Shares of Rigel Pharmaceuticals Inc. RIGL, +1.86% soared 39.5% in premarket trading Friday, after the biotechnology company announced Food and Drug Administration approval of its Rezlidhia leukemia treatment. With trading volume of 5.2 million shares, the stock was the most active ahead of the open.
Seeking Alpha | 2022-11-03 19:25:39
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 AM ET Company Participants Dolly Vance - Senior Advisor, Legal & Corporate Affairs Raul Rodriguez - President and CEO Wolfgang Dummer - Executive Vice President and Chief Medical Officer Dave Santos - Executive Vice President and Chief Commercial Officer Dean Schorno - Executive Vice President and Chief Financial Officer Conference Call Participants Carly Kenselaar - Citi Kristen Kluska - Cantor Fitzgerald Eun Yang - Jefferies Dennis Resnick - BMO Capital Markets Operator Greetings, and welcome to the Rigel Pharmaceuticals Financial Conference Call for the Third Quarter 2022. At this time, all participants are in a listen-only-mode.
Seeking Alpha | 2022-10-31 18:00:50
RIGL hoped to expand the label of its drug Tavalisse (fostamatinib), but the failure of the drug in phase 3 appeared to scupper its chances. RIGL sought guidance to see if a reanalysis of the failed phase 3 study might be well received, but it doesn't appear it was.
Zacks Investment Research | 2022-10-11 12:47:27
Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.
Earnings
| Date | Time | EPS Expected | EPS Reported | % | Revenue Expected | Revenue Reported | % |
|---|---|---|---|---|---|---|---|
| 2022-11-03 | AMC | -0.13 | -0.11 | 15.39% | -- | -- | -- |
| 2022-08-02 | AMC | -0.12 | -0.08 | 33.34% | -- | -- | -- |
| 2022-05-03 | AMC | -0.14 | -0.16 | 14.28% | 14M | 17M | 16.66% |
| 2022-03-01 | AMC | -0.13 | -0.13 | -- | 23M | 20M | -12.75% |
| 2021-11-02 | AMC | -0.1 | -0.12 | 19.99% | 24M | 22M | -8.57% |
| 2021-08-03 | AMC | -0.11 | -0.08 | 27.28% | 20M | 26M | 28.94% |
| 2021-05-05 | AMC | 0.01 | 0.22 | 2100% | 1.5B | 81M | -94.45% |
| 2021-03-02 | AMC | -0.11 | -0.11 | -- | -- | -- | -- |
Due Diligences
These posts should include more in-depth research by the poster about the specific company, sector or trade idea. Including any sources and citations.
$SHPH $BRTX $RIGL $BRSH--on watch for more gains from news and trading activity
​ **$SHPH Shuttle Pharmaceuticals, Inc.** High volume today following a strong Friday. Over 16 million shares traded today. Biotechs responding to good news...finally. SHPH, a specialty pharmaceutical company focused on the development and commercialization of drugs for sensitizing... Read More
Top Discussions
These are the top discussions over the last 24-hours that mention the RIGL stock ticker symbol.
Daily Plays December 19, 2022
Talk about your plays today or things you are on the lookout for. This is where you belong if your comment includes a $Ticker in that format. ​ *keep it civil please*...
Failures to Deliver
Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.
Last Updated: Fri, 3 Dec 2021 12:00 EST
@wsbdaily
wsbdaily